{
    "nct_id": "NCT03365791",
    "official_title": "Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.",
    "inclusion_criteria": "Patients eligible for inclusion in this study had to meet all of the following criteria:\n\n* Patient must have had at least one prior line of therapy for their disease and must not be beyond 4th progression/relapse of disease (5 maximum prior lines).\n* Patient has a pathology confirmed diagnosis of a solid tumor or lymphoma listed in the section \"condition\". Patients must have measurable disease as per appropriate guidelines (Solid Tumors by RECIST 1.1 and Diffuse Large B-cell Lymphoma by Revised Response Criteria for Malignant Lymphoma - Cheson et al 2007).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Patients eligible for this study must not meet any of the following criteria:\n\n* History of severe hypersensitivity reactions to other monoclonal antibodies.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Active, known or suspected autoimmune disease or a documented history of autoimmune disease within three years prior to screening with a few exceptions as per protocol.\n* Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.\n* Patient with second primary malignancy within < 3 years of first dose of study treatment.\n* Prior immunotherapy treatment with PD-1, PD-L1, CTLA-4, or LAG-3 antibodies.",
    "miscellaneous_criteria": ""
}